Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2002 June;21(2) > International Angiology 2002 June;21(2):158-64

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

INTERNATIONAL ANGIOLOGY

Rivista di Angiologia


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,37


eTOC

 

ORIGINAL ARTICLES  


International Angiology 2002 June;21(2):158-64

Copyright © 2003 EDIZIONI MINERVA MEDICA

lingua: Inglese

Decreasing plasma endothelin-1 and unchanged plasma neopterin during folate supplementation in hyperhomocysteinemia

Gottsäter A., Forsblad J., Mattiasson I., Lindgärde F.

Department of Vascular Disease, University of Lund, University Hospital MAS, Malmö, Sweden


PDF  


Back­ground. Hyper­hom­o­cys­tei­ne­mia is a risk fac­tor for ath­ero­scler­o­sis and ­venous throm­bo­sis, prob­ably exert­ing its ­effects ­through endo­the­lial func­tion. Homo­cys­teine lev­els are low­ered by ­folate sup­ple­men­ta­tion, and such treat­ment ­improves endo­the­lial func­tion. How­ev­er, wheth­er ­folate sup­ple­men­ta­tion decreas­es vas­cu­lar risk and ­improves sur­vi­val is ­unknown. The aim of this study was to eval­u­ate endo­the­lial func­tion and mono­nu­cle­ar leu­ko­cyte inflam­ma­to­ry activ­ity dur­ing homo­cys­teine low­er­ing in ­patients with hyper­hom­o­cys­tei­ne­mia and vas­cu­lar dis­ease.
Meth­ods. Endo­the­lial func­tion ­assessed as plas­ma (p-)endo­the­lin(ET)-1 and intra­plate­let cGMP and cAMP, and mono­nu­cle­ar leu­ko­cyte inflam­ma­to­ry activ­ity, ­assessed as p-neop­te­rin were stud­ied dur­ing homo­cys­teine low­er­ing in 50 ­patients with hyper­hom­o­cys­tei­ne­mia and vas­cu­lar dis­ease, ran­dom­ized to ­folate sup­ple­men­ta­tion or no treat­ment for 3 ­months.
­Results. P-homo­cys­teine ­decreased dur­ing the 3 ­months not only in ­patients on ­folate sup­ple­men­ta­tion (from 27 [21-52] to 14 [8-41] µmol/l; p<0.001), but also in the untreat­ed group (from 23 [20-35] to 19 [4-31] µmol/l; p<0.001). P-ET-1 ­decreased dur­ing ­folate sup­ple­men­ta­tion (from 5.7 [2.7-11.6] to 4.1 [1.8-9.0] pg/ml; p<0.01), but was ­unchanged in the untreat­ed group 4.1 [2.0-9.5] pg/ml and 4.5 [2.7-7.1] pg/ml). P-neop­te­rin was ­unchanged in ­patients on ­folate sup­ple­men­ta­tion (9.7 [5.1-54.4] and 7.6 [5.7-73.0] nmol/l), but ­increased in the untreat­ed group (from 8.2 [4.7-19.5] to 8.6 [4.6-24.6] nmol/l; p<0.05). Intra­plate­let cGMP ­decrea-sed in ­patients on ­folate sup­ple­men­ta­tion (from 0.86 [0.21-2.00] plate­lets to 0.56 [0.17-1.42] pmol/109 plate­lets; p<0.05), but was ­unchanged in the untreat­ed group. No sig­nif­i­cant dif­fer­enc­es con­cern­ing intra­plate­let cAMP ­occurred in ­either group.
Con­clu­sions. ­Folate sup­ple­men­ta­tion in hyper­hom­o­cys­tei­ne­mia is asso­ciat­ed with decreas­ing lev­els of both ET-1 and intra­plate­let cGMP, and the ­absence of an ­increase in the lev­els of the inflam­ma­to­ry medi­a­tor neop­te­rin.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail